{"id":51415,"title":"Cambridge Start Up Model Unlocks £65 Million Biotech Deals","publisher":"Stockmark.IT","author":"Stockmark.IT Website","published":"2026-03-26T08:27:21+00:00","modified":"2026-03-26T05:31:54+00:00","canonical_url":"https://stockmark.it/cambridge-start-up-model-unlocks-65-million-biotech-deals/","markdown_url":"https://stockmark.it/cambridge-start-up-model-unlocks-65-million-biotech-deals.md","json_url":"https://stockmark.it/cambridge-start-up-model-unlocks-65-million-biotech-deals.json","category":"Biotech","categories":["Biotech"],"featured_image":"https://i0.wp.com/stockmark.it/wp-content/uploads/2026/03/stencil.default-2026-03-26T053028.239.webp?fit=1200%2C800&quality=80&ssl=1","format":"news","language":"en-GB","content":"The University of Cambridge is reaping substantial rewards from its innovative approach, granting six seasoned entrepreneurs a golden access card to explore its departments for breakthrough technologies ready for rapid commercialisation. One notable biotech venture, Immutrin, recently secured £65 million in funding, led by prominent Silicon Valley investors such as Frazier Life Sciences. This company is focused on developing antibody therapies aimed at repairing the heart following attacks.\n\nImmutrin was co-founded by Cambridge Innovation Capital, a key investor for the University of Cambridge, which spearheads this access initiative. The driving force behind Immutrin, Mihriban Tuna, has a rich background as a former chief scientific officer at Adaptate Biotherapeutics and currently serves as the company’s chief executive. Andrew Williamson, managing partner at Cambridge Innovation Capital, underscored the significance of this validation, highlighting the attraction of high-calibre investors to the innovative work undertaken by the entrepreneurs in residence.\n\nThe approach to bridge academic research with practical business experience is gaining traction. Various other universities including Surrey, Glasgow, and Oxford have established similar initiatives featuring experts or entrepreneurs in residence. The University of Southampton is actively seeking up to six experts-in-residence, offering a salary of £25,000. Notably, the Royal Society’s programme has supported over 130 placements since its inception in 2018, demonstrating a growing recognition of the need for commercial insight in academic research.\n\nCambridge Innovation Capital distinguishes itself by offering competitive salaries akin to market rates for C-suite positions in start-ups, coupled with the potential for equity in new ventures. Williamson asserts the importance of aligning leading technology with astute business acumen. He argues that world-class teams can transform flawed technologies into market-ready products, while subpar management can derail even the most promising innovations.\n\nFinding individuals who possess a blend of deep technological expertise and entrepreneurial spirit remains a challenge. The intersection of these attributes forms a small circle within the larger talent pool. Last summer, Cambridge Innovation Capital committed £100 million to support emerging businesses from its entrepreneurs in residence initiative.\n\nOne of the notable entrepreneurs, Ferenc Huszar, previously led research at Magic Pony, a visual processing specialist acquired by Twitter in 2016. Huszar is currently involved in fostering start-ups in the exciting realm of AI, which is aimed at enhancing coding practices.\n\nEntrepreneurs in residence are a common feature within international venture capital firms. Cambridge Innovation Capital leverages its unique partnership with Cambridge University to attract top-tier candidates. The appeal lies in the access to a vast reservoir of innovation, enabling entrepreneurial leaders to collaborate with researchers eager to commercialise their technologies.\n\nDamian Crowther, another entrepreneur in residence, transitioned from his role as head of early drug discovery at AstraZeneca to join Cambridge Innovation Capital. His initial research identified potential drug discovery areas that piqued commercial interest, leading to the creation of Trimtech Therapeutics. Supported by early-stage capital from Cambridge Innovation Capital, Trimtech raised £25 million from leading investors.\n\nWilliamson notes that while all researchers at Cambridge excel in their fields, the commercial viability of their ideas can vary significantly. It is crucial to have the foresight to determine which concepts are ready for the market versus those requiring further fundamental research, ensuring effective capital allocation."}